Chinese biopharmaceutical firm Akeso announced on Wednesday that its immunotherapy drug had outperformed AstraZeneca\u2019s Imfinzi in a head-to-head phase-three trial for biliary tract cancer.<\/p>\n
The result represents another breakthrough for Akeso\u2019s ivonescimab \u2013 which has already been licensed by the US firm Summit Therapeutics in a multibillion-dollar deal \u2013 as China\u2019s biopharma industry increasingly looks to compete on the global stage.<\/p>\n
The Chinese trial tested ivonescimab and chemotherapy against AstraZeneca\u2019s Imfinzi (durvalumab) plus chemotherapy on a total of 682 patients with advanced biliary tract cancer \u2013 a particularly deadly form of cancer with a five-year survival rate of less than 5 per cent, according to a Nature study.<\/p>\n
The results showed that patients taking Akeso\u2019s novel drug lived longer than those using the AstraZeneca treatment, the company said in a Hong Kong stock exchange filing released a day ahead of its interim results.<\/p>\n
The study marks the first positive phase-three study for ivonescimab in gastrointestinal tumours, potentially opening the door for the drug to be used in a \u201cbroader range of solid tumours\u201d, said Xia Yu, Akeso\u2019s founder, chairwoman and CEO.<\/p>\n
However, Akeso has yet to disclose the exact survival figures from the trial, which the Zhongshan-headquartered company is expected to present at an coming conference.<\/p>\n","protected":false},"excerpt":{"rendered":"Chinese biopharmaceutical firm Akeso announced on Wednesday that its immunotherapy drug had outperformed AstraZeneca\u2019s Imfinzi in a head-to-head…\n","protected":false},"author":2,"featured_media":111907,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[20662],"tags":[46047,11153,46051,255,26472,23728,1772,38452,25687,24141,46050,4946,24855,46048,46049],"class_list":["post-111906","post","type-post","status-publish","format-standard","has-post-thumbnail","category-astrazeneca","tag-akeso","tag-astrazeneca","tag-biliary-tract-cancer","tag-china","tag-durvalumab","tag-hang-seng-index","tag-hong-kong","tag-hong-kong-stock-exchange","tag-imfinzi","tag-ivonescimab","tag-macquarie-capital","tag-nature","tag-nomura","tag-xia-yu","tag-zhang-jialin"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@UnitedKingdom\/117165234878154607","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/posts\/111906","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/comments?post=111906"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/posts\/111906\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/media\/111907"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/media?parent=111906"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/categories?post=111906"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/tags?post=111906"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}